{"nctId":"NCT01499953","briefTitle":"Superficial Vein Thrombosis (SVT) Treated With Rivaroxaban Versus Fondaparinux","startDateStruct":{"date":"2012-04"},"conditions":["Superficial Vein Thrombosis"],"count":472,"armGroups":[{"label":"Rivaroxaban","type":"EXPERIMENTAL","interventionNames":["Drug: Rivaroxaban"]},{"label":"Fondaparinux","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: Fondaparinux"]}],"interventions":[{"name":"Rivaroxaban","otherNames":["Xarelto"]},{"name":"Fondaparinux","otherNames":["Arixtra"]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* acute symptomatic supragenual superficial vein thrombosis of the leg\n* at least one of the following major risk factor for VTE:\n* age \\> 65 years or\n* male sex or\n* history of DVT/PE/SVT or\n* history of cancer or active cancer or\n* autoimmune disease or\n* SVT of a non-varicose vein\n* thrombus extension of at least 5 cm\n* proximal thrombus end with more than 3 cm distance to the saphenofemoral junction (SFJ)\n* age \\> 18 years\n* written informed consent\n\nExclusion Criteria:\n\n* other indication for therapeutic anticoagulation such as acute deep vein thrombosis, acute pulmonary embolism, atrial fibrillation with indication for anticoagulant therapy\n* any PE or DVT within last 6 months before inclusion\n* clinical signs of PE without objective exclusion (CT or VQ scan, angiography)\n* SVT without signs of thrombotic/inflammatory activity (activity signs: diameter \\> 4 mm, pain, redness, elevated local or systemic temperature)\n* SVT after sclerotherapy\n* Duration of symptoms \\> 3 weeks\n* pretreatment of more than 72 h with therapeutic dosages of oral or parenteral anticoagulants\n* pretreatment of more than 5 days with subtherapeutic oral or parenteral anticoagulants\n* indication for escalated antiplatelet therapy (monotherapy with aspirin \\> 325 g/d and any dual antiplatelet therapy)\n* SVT closer than 3 cm to saphenofemoral junction (SVJ)\n* anticipated superficial vein surgery within 90 days\n* anticipated thrombolytic therapy within 90 days\n* manifest clinically relevant bleeding\n* clinically relevant bleeding in the last 30 days before study inclusion\n* major surgery within last 30 days before inclusion\n* ophthalmic, spinal or cerebral surgery within last 90 days\n* severe head trauma within last 90 days\n* hemorrhagic stroke within last 12 months\n* hereditary or acquired severe hemorrhagic diathesis\n* gastrointestinal bleeding within last 90 days requiring endoscopy\n* uncontrolled arterial hypertension (systolic \\> 180 mm Hg, diastolic \\> 110 mm Hg)\n* acute endocarditis\n* low platelet count (\\< 100 x 109/l)\n* Prothrombin time \\< 50 %\n* calculated creatinine clearance \\< 30 ml/min\n* significant liver disease such as acute hepatitis, chronic active hepatitis, cirrhosis\n* life expectancy \\< 3 months\n* any contraindications listed for rivaroxaban or fondaparinux\n* women of child bearing potential without safe contraception method\n* pregnant or breastfeeding women\n* participation in another trial with pharmacological intervention","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Rate of Objectively Confirmed VTE Complications","description":"The primary efficacy outcome was the composite of death from any cause, symptomatic pulmonary embolism (confirmed by ventilation-perfusion scanning, helical computed tomography, pulmonary angiography, or autopsy), symptomatic deep vein thrombosis (confirmed by ultrasonography or venography), or symptomatic extension towards the saphenofemoral junction or symptomatic recurrence of superficial vein thrombosis (confirmed by ultrasonography) up to day 45.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"7","spread":null},{"groupId":"OG001","value":"4","spread":null}]}]}]},{"type":"SECONDARY","title":"Composite Primary Efficacy Outcome","description":"For this, secondary efficacy outcomes were the composite primary efficacy outcome up to Day 90 and the following outcomes up to Day 45 and Day 90: each component of the primary efficacy outcome, the rate of major VTE (composite of symptomatic pulmonary embolism or symptomatic proximal DVT or VTE-related death) and the rates of surgery for SVT.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"15","spread":null},{"groupId":"OG001","value":"15","spread":null}]}]}]},{"type":"SECONDARY","title":"Rate of Major VTE","description":"composite of:\n\n* symptomatic pulmonary embolism\n* symptomatic proximal DVT\n* VTE-related death","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"6","spread":null},{"groupId":"OG001","value":"2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]}]},{"type":"SECONDARY","title":"Rates of Surgery for SVT","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"2","spread":null}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Major Bleeding (Main Safety Outcome)","description":"* associated with a fall of hemoglobin of 2 g/l or more, or;\n* leading to a transfusion of 2 or more units of packed red blood cells or whole blood, or;\n* occurring into a critical site such as intracranial, intraspinal, intraocular, pericardial, intraarticular, intramuscular with compartment syndrome, retroperitoneal, or;\n* fatal bleeding.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Clinically Relevant Non-major, Minor and Total (Any) Bleeding","description":"Clinically relevant, non-major bleeding is defined as any overt bleeding and\n\n* associated with a medical intervention, or\n* unscheduled contact with the physician (presence or telephone contact)\n* temporary or complete cessation of study drug\n* associated with any relevant discomfort to the patient (pain, impairment of activities of daily life)","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"6","spread":null},{"groupId":"OG001","value":"1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"15","spread":null},{"groupId":"OG001","value":"15","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"20","spread":null},{"groupId":"OG001","value":"16","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":3,"n":235},"commonTop":[]}}}